Today's 30 items: 10 medchem (DCAF16 degraders, a brain-penetrant caspase-2 inhibitor), 5 pharmacology (VRC01 breakthrough resistance), 8 computational (benchmark and docking caveats), and 7 industry stories led by AstraZeneca's reported Rhythm bid and the Zolgensma tumor reports.
2026-11-05 · ⚗️DCAF16-recruiting targeted protein degraders · Journal of Medicinal Chemistry
- This perspective reviews the medicinal chemistry of degraders that recruit the E3 ligase DCAF16, motivated by the field's heavy reliance on CRBN and VHL.
- It catalogs the growing variety of DCAF16-recruiting motifs and discusses structural rationale and SAR of representative bifunctional and monovalent degraders, including clinical-stage examples PLX-61639 and AMX-883.
- It closes with remaining challenges and suggested design strategies for clinical translation.
💡 PointsBased on the abstractDoes DCAF16 actually earn a place next to CRBN and VHL? Its draw is that monovalent, low-molecular-weight covalent handles can recruit it, sidestepping PROTAC size and permeability penalties. The catch is that many hits look cysteine-reactive, so I'd ask how much target scope is real versus ligand-specific, and whether proteome-wide selectivity holds.
Beyond CRBN and VHL: DCAF16-Recruiting Degraders from Rational Design to Clinical Translation ↗
2026-11-05 · ⚗️Dual PARP/tubulin colchicine-site small-molecule inhibitors · Journal of Medicinal Chemistry
- Benzofused heterocyclic carboxamides were designed as single molecules hitting both PARP and the tubulin colchicine-binding site, aiming to counter tumor heterogeneity and resistance.
- SAR work led to D13, which showed low-nanomolar antiproliferative activity across several cancer lines with good selectivity over normal cells, inhibited PARP1/2, and blocked tubulin polymerization.
- D13 caused G2/M arrest, DNA damage and apoptosis, limited migration and tube formation, and in an MDA-MB-231 xenograft outperformed veliparib, phenstatin and their combination with good tolerability.
💡 PointsBased on the abstractDual PARP/colchicine-site agents are tough to balance: the two pharmacophores want different shapes, so I'd check that D13 isn't just a potent tubulin binder with incidental PARP activity. Key controls are PARP-null or BRCA-proficient cells, and a tubulin-inactive analog. Also, tubulin toxicity could erode the therapeutic window that PARP inhibitors normally enjoy.
Identification and Optimization of Novel Dual PARP/Tubulin Colchicine-Binding Site Inhibitors for Cancer Therapy ↗
2026-11-05 · ⚗️Mycobacterium tuberculosis type II NADH dehydrogenase (small molecule) · Journal of Medicinal Chemistry
- SAR and structure-property work on tricyclic spirolactam (TriSLa) Ndh inhibitors addressed the metabolic instability of earlier analogs and yielded BDM91465.
- Cryo-EM placed the compound in the menaquinone pocket of Ndh, consistent with the SAR.
- It showed favorable pharmacokinetics, with exposure sustained above its MIC.
- In mice it lowered bacterial burden, mirroring genetic Ndh-2 inactivation and supporting Ndh-2 as a druggable target.
💡 PointsBased on the abstractFixing metabolic liability while keeping the quinone-pocket fit is the hard part with Ndh-2 inhibitors; earlier phenothiazine-type binders were never drug-like enough to test the target. Mouse efficacy mirroring genetic inactivation is a strong validation. I'd ask about resistance frequency, activity against drug-resistant strains, and combination behavior in a regimen, since TB is never monotherapy.
Design and Synthesis of Metabolically Stable Tricyclic-SpiroLactams Inhibitors of Mycobacterium tuberculosis Type-II NADH Dehydrogenase: Structure−Activity and Structure−Property Relationship Studies ↗
2026-11-05 · ⚗️METTL1 RNA methyltransferase inhibitors · Journal of Medicinal Chemistry
- Conventional SAR was combined with a tandem nanoscale direct-to-biology workflow to develop inhibitors of the tRNA m7G methyltransferase METTL1/WDR4.
- Lead VK238 inhibited the enzyme at nanomolar concentrations with selectivity across methyltransferase and kinase panels, and lowered tRNA m7G levels in cells, triggering apoptosis in several AML lines.
- Biophysical assays, photoaffinity labeling and docking indicated the series binds in the SAM pocket of METTL1.
💡 PointsBased on the abstractD2B earns its keep here by compressing make-test cycles, but crude-mixture hits are notorious for false positives, so resynthesized, purified VK238 is what counts. METTL1 SAM-pocket binders risk cross-reactivity with other methyltransferases, so I'd want cellular target engagement and a rescue experiment with catalytically dead METTL1 to link AML killing to on-target inhibition.
Development of Potent METTL1 Inhibitors Using a Nanoscale Direct-To-Biology Strategy ↗
2026-11-05 · ⚗️Caspase-2 covalent-reversible peptidomimetic inhibitor · Journal of Medicinal Chemistry
- A broad SAR campaign on covalent-reversible peptidomimetics mapped the S2-S3 region of the caspase-2 binding site and identified 2-methylindoline-2-carboxylic acid and quinaldic acid as stable P5 groups.
- Swapping the aldehyde warhead for a nitrile in one step sharpened selectivity over other caspases while keeping potency, giving MUR-2425.
- MUR-2425 blocked formation of the neurotoxic Δtau314 fragment in vitro, showed stable ADMET behavior across species, reached the brain in mice, and bound covalently in a co-crystal structure.
💡 PointsBased on the abstractNitrile for aldehyde is the right call: aldehydes are metabolically and chemically fragile, and reversible covalent nitriles usually keep potency with cleaner caspase selectivity. But the peptidomimetic backbone still worries me for brain exposure. I'd want brain-to-plasma unbound ratios, efflux data, and a kinact/KI readout against caspase-3/7 before calling it a tool compound.
Refinement of Peptidomimetics toward MUR-2425: A Brain-Penetrant and Selective Caspase-2 Inhibitor with Enhanced Pharmacokinetics ↗
2026-11-05 · ⚗️Quinoline-based THRβ-selective agonists · Journal of Medicinal Chemistry
- Aiming to improve on resmetirom's limited THRβ/THRα selectivity, scaffold hopping produced a new quinoline-based THRβ agonist series.
- SAR optimization gave compound 24, a potent agonist with clear THRβ preference over THRα, good oral bioavailability and higher liver exposure than resmetirom.
- In animal models it improved metabolic parameters and reduced hepatic lipid buildup, inflammation and fibrosis, without evident thyroid-axis disruption or THRα-linked cardiac effects, and was well tolerated at high doses.
💡 PointsBased on the abstractResmetirom set the bar, so the question is what quinoline buys over its pyridazinone core: selectivity, liver targeting, or just IP space. Compound 24's higher liver exposure is encouraging, but I'd want THRα and THRβ functional data in cell reporter assays, plus OATP-mediated uptake and a look at whether the quinoline raises CYP or hERG liabilities.
Discovery of Quinoline-Based Highly Potent and Selective THRβ Agonists for MASLD Treatment ↗
2026-11-05 · ⚗️CaMKIIα hub domain (small molecule) · ACS Medicinal Chemistry Letters
- Building on the thiazole ligand PTCA, the authors explored related five-membered sulfur heterocycles that bind the CaMKIIα hub domain, the high-affinity site of GHB.
- Greater saturation and chirality were introduced to diversify the scaffold while keeping physicochemical properties favorable.
- Activity depended on the presence and position of sulfur relative to the carboxylic acid, with stereoselective recognition.
- Two mid-nanomolar ligands showed good cellular permeability and were not efflux transporter substrates.
💡 PointsBased on the abstractA neat move away from flat aromatic PTCA toward saturated, chiral S-heterocycles: more sp3 character and stereo-resolved SAR suggest a real hub-pocket fit, not nonspecific acid binding. Caveat: a carboxylic acid yet good permeability is surprising. Next I'd check selectivity against other GHB-site proteins, brain exposure, and a crystal structure to rationalize why sulfur position matters.
Exploring Five-Membered S -Heterocyclic Scaffolds As Novel CaMKIIα Ligands Targeting the Hub Domain ↗
2026-11-05 · ⚗️eIF4E-eIF4G interaction (helical peptidomimetic foldamer) · Journal of Medicinal Chemistry
- Short helical sulfonyl-γ-AApeptides were designed to mimic the eIF4G1 alpha-helical motif and bind eIF4E directly.
- Structure-guided stereochemical remodeling gave a compact right-handed foldamer with strong proteolytic stability, submicromolar affinity and potent inhibition of cap-dependent translation.
- Exploiting lysosome-centered signaling in cancer cells, a conjugate delivered the inhibitor intracellularly.
- The conjugate suppressed ferritin translation, causing lipid peroxidation, ferroptosis and in vivo antitumor activity.
💡 PointsBased on the abstractHelical foldamers beat stapled peptides on protease stability, but submicromolar affinity is modest next to eIF4E's cap-site binders, and the cell story rests on a lysosome-directed conjugate. Where is the control? I'd want an inactive stereoisomer conjugate and a ferroptosis rescue with iron chelation or ferrostatin, to show effects come from eIF4E blockade rather than the carrier.
Compact Sulfonyl-γ-AApeptide Foldamers for Targeting Translation Initiation Machinery Assembly ↗
2026-11-05 · ⚗️Cardiac myosin (allosteric small molecule) · ACS Medicinal Chemistry Letters
- Ulacamten was optimized from a diketopiperazine screening hit whose biochemical behavior differed from that of mavacamten and aficamten.
- It acts at a different binding site from those approved cardiac myosin inhibitors and is orally available.
- In healthy and obese ZSF1 rats it lowered left ventricular fractional shortening; human Phase 1 data showed a half-life supporting steady state within about a week.
- It is being tested in the Phase II AMBER-HFpEF trial (NCT06793371).
💡 PointsBased on the abstractUlacamten's real question is differentiation: if the site really differs from mavacamten and aficamten, does it give a gentler, less steep exposure-to-contractility relationship? HFpEF patients have little systolic reserve, so that window matters more than potency. I'd want ATPase selectivity against skeletal and smooth muscle myosin and a full dose-response of fractional shortening.
The Discovery of Ulacamten, a Cardiac Myosin Inhibitor for the Treatment of Heart Failure with Preserved Ejection Fraction ↗
2026-11-03 · ⚗️PD-L1 (small molecule) · ACS Medicinal Chemistry Letters
- A series of N-acyl pyrimidine-biphenyl analogues was designed as small-molecule PD-L1 inhibitors; A6 and A12 were potent binders in a reporter assay.
- Molecular dynamics attributed A6's slight edge to persistent interaction with D122.
- A6 disrupted PD-1/PD-L1 binding in ELISA, restored T cell activity, boosted cytokine secretion and enhanced T cell-mediated tumor cell killing.
- In the syngeneic 4T1 model it suppressed tumor growth without systemic toxicity.
💡 PointsBased on the abstractBiphenyl cores are the familiar BMS-type PD-L1 pharmacophore, so novelty rides on the N-acyl pyrimidine. Those biphenyls induce PD-L1 dimerization, and the D122 story comes only from MD. I'd want a co-crystal or NMR, human versus mouse PD-L1 affinity (4T1 is murine), and a SPR KD with solubility data before trusting the potency ranking.
Discovery of N -Acyl Pyrimidine-Biphenyl Small-Molecule PD-L1 Inhibitors that Restore T Cell Function and Suppress Tumor Growth in Breast Cancer ↗
2026-11-05 · 🧬Hepatic CYP enzymes (CYP3A); small-molecule hepatotoxicant DDC · Chemical Research in Toxicology
- Untargeted metabolomics in mouse liver S9 fractions identified several CYP-dependent metabolites of the porphyria-inducing chemical DDC.
- CYP3A contributed to multiple biotransformation routes, including a previously undescribed pathway involving deamination followed by cyclization.
- In mice lacking Cyp3a, DDC-driven N-methyl protoporphyrin IX formation, protoporphyrin accumulation and liver injury were not appreciably altered, so CYP3A appears dispensable for generating this porphyrin.
💡 PointsBased on the abstractGood news for anyone worried about CYP3A-mediated DDC bioactivation: the Cyp3a-null result says NMPP formation runs through other P450s, so CYP3A inhibitors or inducers won't be the lever here. Next step is isoform mapping with other Cyp families, or a Cyp reductase knockout, since redundancy likely masks the culprit. Mouse-to-human porphyrin handling also needs checking before reading across.
Roles of Hepatic Cytochrome P450 Enzymes in 3,5-Diethoxycarbonyl-1,4-dihydrocollidine (DDC) Metabolism and N-Methyl Protoporphyrin IX Formation ↗
2026-11-05 · 🧬H2S-donor (isothiocyanate)–metformin hybrid small molecule · British Journal of Pharmacology
- Met-ITC joins metformin to an H2S-releasing isothiocyanate, aiming to add vascular benefit without losing antidiabetic action.
- Computational profiling suggested better permeability than metformin; glucose-lowering activity persisted in liver cells and diabetic mice.
- In endothelial and smooth muscle cells it limited oxidative stress, cell death and senescence more effectively than metformin, and relaxed rat aortic rings with or without endothelium.
💡 PointsBased on the abstractA hybrid only earns a next study if the H2S arm adds something metformin can't. Here the rat aortic relaxation is the cleanest proof of that, but it's an isolated-tissue effect at unspecified exposure. I'd want PK showing intact hybrid versus released ITC and H2S in vivo, plus a metformin-matched db/db comparison on vascular endpoints, and checks on ITC reactivity and off-target thiol effects.
The H2S-releasing metformin hybrid Met-ITC protects against diabetes-associated vascular dysfunction preserving glycaemic control ↗
2026-11-05 · 🧬PDE5 inhibitor (tadalafil); cGMP/PKG signalling and HDAC2 · British Journal of Pharmacology
- In rat models of lung fibrosis induced by bleomycin or paraquat, daily tadalafil lessened fibrosis and lung injury, including when treatment began at an advanced stage.
- Benefit appeared to run through cGMP/PKG signalling, dampening TGF-β/Smad activity and epithelial-mesenchymal transition.
- Preliminary data point to PKG lowering HDAC2; silencing or inhibiting HDAC2 mimicked the drug, while overexpressing it reversed the effect. The authors suggest clinical evaluation for repurposing.
💡 PointsBased on the abstractTadalafil's appeal is a known human safety profile, but PDE5 inhibitors have already been tried in fibrotic lung disease with modest signal, so the rat data need to beat that history. Bleomycin and paraquat resolve spontaneously and poorly mimic human IPF; I'd want exposure at the efficacious dose compared with human levels, plus HDAC2 and EMT readouts in patient-derived lung fibroblasts or tissue.
Pharmacological targeting of phosphodiesterase-5 halts pulmonary fibrosis by suppressing epithelial-mesenchymal transition via cGMP/PKG/Smad/HDAC2 pathway ↗
2026-11-04 · 🧬Gadolinium-based contrast agents (macrocyclic gadoterate meglumine, linear gadopentetic acid) vs free GdCl3 · Chemical Research in Toxicology
- Human SH-SY5Y neuroblastoma cells were exposed to a macrocyclic agent, a linear agent and free gadolinium chloride.
- Both chelated agents produced mild immunogenic cell death signals, including ATP and HMGB1 release and calreticulin relocation; free gadolinium did not.
- Linear agent uptake appeared clathrin-dependent. Findings come from a single in vitro cell line, limiting clinical inference.
💡 PointsBased on the abstractMild DAMP release from both chelated agents, but not from free Gd, hints the intact complex is doing something, which is not what the free-ion toxicity story predicts. The catch is exposure: nobody has shown neurons see these concentrations behind an intact blood-brain barrier. Next step is a dose series against realistic brain levels, with primary neurons or microglia co-culture to test whether any signal propagates.
Gadolinium-Based Contrast Agents Stimulate Adaptive Immune Response through Release of DAMP Signals in Neuronal SH-SY5Y Cells ↗
2026-11-04 · 🧬VRC01 (CD4-binding-site broadly neutralizing monoclonal antibody) for HIV-1 prevention · Science Translational Medicine
- Follow-up analysis of two parallel Antibody Mediated Prevention trials of the CD4-binding-site antibody VRC01, tracking HIV-1 acquisition through the final study visit.
- Against viruses highly sensitive to VRC01, prophylaxis conferred substantial protection, consistent with blocking or clearing such infections.
- After dosing ended, antibody groups showed more diagnoses and resistance than placebo, including moderately sensitive or resistant viruses, suggesting waning levels let resistant strains establish; combinations of antibodies are likely needed.
💡 PointsBased on the abstractThis reads as a classic exposure problem: a single bnAb only protects while concentrations stay above the neutralization threshold for a given strain, and as levels decay through the dosing interval, the trough becomes a selection window for less sensitive virus. Next steps are engineered Fc-extended antibodies for flatter exposure and combinations covering escape, with titers tied to protection.
Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections ↗
2026-11-06 · 💻Active-learning-guided docking over kinase fragment recombination spaces (case study: protein kinase A) · chemRxiv
- Couples subpocket-aware fragment recombination from KinFragLib with docking, a machine-learning surrogate and genetic-style add/delete/swap moves around already-scored ligands.
- Retrospective case study on PKA with a recombination space of roughly 210,000 ligands.
- Needed docking for only a small fraction of the space, and a greedy strategy recovered about half of the best ligands, clearly beating random picks.
- A diversity-aware variant widened fragment and hinge-binder coverage with little loss in performance.
💡 PointsBased on the abstract"About half of the best ligands" is only meaningful against a docking score, and that score is the ground truth here, so this measures how well a surrogate reproduces Vina-type scoring, not affinity. Also one kinase, retrospective, with the whole space presumably pre-docked. On my project I'd ask for a second target and a synthesizability or experimental check before trusting the recombined hits.
Active Learning for Fragment-Based Kinase Inhibitor Discovery using Docking ↗
2026-11-06 · 💻Benchmarking of generative protein motif-scaffolding models, with MD-based validation · arXiv
- BILBY-PRO is a benchmark of conserved functional motifs drawn systematically from PROSITE-linked structures, used to compare six recent scaffold generators on target coverage and unique-solution yield.
- BILBY-MD adds all-atom simulations against references, tracking motif and scaffold drift, contacts and dihedral landscapes.
- Many statically solved MotifBench designs fail the MD criteria, especially context-dependent motifs, so refolding success alone does not show dynamical fidelity.
💡 PointsBased on the abstractWhether a design "fails" MD hinges on simulation length, replicate count and force field, so I'd want failure rates to hold across seeds before trusting any ranking of generators. Still, on my own project a refolding hit is only a first filter: a motif that drifts early in unrestrained MD rarely keeps the precise geometry that function needs, and I'd rather learn that before ordering genes.
Static Recovery Is Not Dynamic Stability: Dynamics-Aware Benchmarking of Protein Motif Scaffolding ↗
2026-11-06 · 💻Diffusion-based molecular docking (pose prediction) · arXiv
- Using DiffDock under a fixed training budget, the study compares ordinary continued training with torsion-focused supervision and a mixture of the two.
- Evaluation separates score fidelity, pose quality, best-of-10 sampling and confidence-ranked Top-1 success.
- Broad continuation gave the best Top-1 success among trained variants, while focused or mixed supervision showed no consistent gain.
💡 PointsBased on the abstractA null result like this is useful, but Top-1 depends on DiffDock's confidence model, which the post-training may not touch, so a gain in score fidelity could be invisible there. I'd want seed variance, the PDBBind-to-PoseBusters gap, and success under a physical-validity filter. Would it survive on our own cross-docking targets, rather than a held-out benchmark?
Geometric Relevance Is Not Sufficient: Evaluating Focused Post-Training Supervision in Diffusion Docking ↗
2026-11-06 · 💻Diagnostics for learned equilibrium samplers and free-energy estimation · chemRxiv
- Shows analytically that self-normalized diagnostics such as effective sample size cannot detect basins a learned sampler never visits, so free energies are biased while confidence intervals look tight.
- Tested on a toy double well, exactly enumerated spin-glass instances and an alanine dipeptide Boltzmann generator, where masked diffusion and GFlowNet intervals often missed the truth.
- A reverse check scored against an independent reference sampler caught the omitted states, and peptide and miniprotein comparisons suggest such omissions can matter for lead optimization.
💡 PointsBased on the abstractESS and bootstrap intervals only measure agreement among samples the model actually draws, so a tight interval speaks to precision, never to coverage. It is the same trap as an MD run stuck in one rotamer with a beautiful block-average error bar. On our own project, would we notice a missing cryptic-pocket or alternative-pose basin without an orthogonal reference such as replica exchange?
False Confidence in Generative Samplers: Exact Physical References Expose Hidden Errors and Diagnostic Blindness ↗
2026-11-06 · 💻Small-molecule target prediction (polypharmacology) · chemRxiv
- PPB4 is a deep neural network trained on ChEMBL35 to forecast which targets a query molecule will hit.
- Unlike its predecessor PPB3 and similar tools, it also flags likely inactive targets, and targets where the molecule resembles both active and inactive compounds.
- Each prediction comes with the nearest training-set neighbors annotated as active; two prospective case studies illustrate use, and the tool is freely available online.
💡 PointsBased on the abstractAn "inactive" call is only as good as the negatives behind it, and ChEMBL negatives are sparse, assay-dependent and often just a single-concentration miss. I'd want to know how the inactive class is defined and whether it was scored against held-out confirmed inactives, not only actives. On my own project I'd first test it on known off-targets of my chemotype before trusting it to trim a counter-screen panel.
Predicting Active and Inactive Targets of Small Molecules from ChEMBL Data Using the Polypharmacology Browser PPB4 ↗
2026-11-06 · 💻LLM-based small-molecule generation (unconstrained and reference-guided) · chemRxiv
- Four open-source LLMs were tested at full precision and three quantization levels for local molecule generation.
- Tasks were free generation and generation guided by a set of kinase inhibitors given in the prompt.
- Quantization raised throughput without hurting validity, diversity or other quality metrics in free generation.
- Following the reference chemical space differed sharply by model, and one model lost it at the lowest precision.
💡 PointsBased on the abstractValidity and diversity are weak yardsticks here; both can stay flat while the output drifts away from the chemistry you asked for. For reference-guided design the number I'd want is similarity to the supplied kinase set, plus novelty against it, and a hinge-binder or scaffold check. A model that quietly stops following the prompt at low precision would still look fine on free-generation metrics. On my own project I'd run that reference-adherence test at the exact quantization level I plan to deploy, per model.
Lost in Chemical Space: Local Open-Source Large Language Models Display Model-Dependent Adherence to Reference Data in Molecular Generation ↗
2026-11-06 · 💻Drug-blind prediction of compound-induced transcriptional responses · bioRxiv
- Existing models of drug-induced expression changes turned out to rely very little on the compound itself; UnDetect separates shared context from compound-specific effects.
- It fuses structure, targets, mechanism and Cell Painting information in a kernel tolerant of missing data, and transfers residual responses across cell lines.
- On drug-blind L1000 and DeepCE benchmarks it outperformed published models, and cross-cell-line transfer helped in nearly all LINCS and Tahoe-100M evaluations.
💡 PointsBased on the abstractIf earlier models barely used the compound, a context-only predictor is the baseline that matters, so I'd look at how much gain survives over it when test compounds are scaffold-distinct, not just drug-blind. L1000 signatures are noisy, so average correlations can flatter; I'd want replicate-level ceilings. On my project, would it rank close analogs of one series correctly?
Predicting Transcriptional Responses to Unseen Compounds through Context Modeling and Multi-View Transfer ↗
2026-11-05 · 💻Protein language model benchmarking (zero-shot, supervised, transfer learning) · bioRxiv
- Protify is an open-source, low-code platform that puts zero-shot, supervised and transfer-learning evaluation of protein language models under one standardized pipeline.
- It was used on ProteinGym and a broad supervised panel covering enzymes, GO annotation, interactions and localization; no single model dominated, and gaps between leaders were within run-to-run noise.
- On enzyme optimal pH, a generic probe matched a specialized model, but under a homology-controlled split pooled-embedding probes lost nearly all signal, so rankings depend heavily on evaluation design.
💡 PointsBased on the abstractIf the leaders sit inside seed noise, a leaderboard ordering is mostly a coin flip, so I'd want variance bars before trusting any rank. The pH result is the sharper warning: a probe that looks competitive on random splits but collapses once near-homologs are removed was probably reading sequence similarity. On my own target family, I'd rerun at a strict identity cutoff first.
Protify: A Benchmarking Platform Revealing Task Dependence and Homology Leakage in Protein Language Model Evaluation ↗
2026-11-06 · 🏢pipeline-progress · BioSpace · Merck; Moderna
- In the Phase 3 INTerpath-001 melanoma study (1,137 patients), intismeran autogene plus Keytruda cut recurrence or death risk by 42% (HR 0.58).
- A manufactured vaccine reached 99% of patients assigned to it; 82% of screened patients had enough tumor tissue.
- Of those, 91% received the full set of up to 34 neoantigens, and the rest still got a shot with fewer targets.
- Merck and Moderna are also testing it in kidney, lung and bladder cancer.
💡 PointsBased on public reportsThe efficacy number gets the headlines, but the 99% manufacturing success rate is what a payer and a competitor should study. Bespoke-per-patient products have usually died on logistics, and this one scaled across 1,137 patients. With Keytruda facing patent expiry, Merck is building a follow-on franchise on top of its own anchor drug, and Moderna gets a credible path beyond respiratory vaccines.
Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market ↗
2026-11-05 · 🏢m-and-a · BioSpace · Rhythm Pharmaceuticals; AstraZeneca
- The Wall Street Journal, citing anonymous sources, reported that AstraZeneca offered about $10 billion, or $124 per share, for Rhythm; the deal is unconfirmed.
- BioSpace found no comment from either company, and Rhythm shares closed up 24% on Wednesday.
- Rhythm's MC4R drug Imcivree brought in $92.1 million in third-quarter sales and gained a hypothalamic obesity approval in March.
💡 PointsBased on public reportsIf accurate, this is AstraZeneca paying for a commercial rare-disease franchise rather than a pipeline option: Imcivree's $92.1 million quarter is modest against a $10 billion price, so the premium is really for MC4R biology and the hypothalamic obesity label. I'd read it as a hedge against crowded incretin obesity, buying a differentiated, orphan-protected niche. Rival bidders would likely prize the same scarcity.
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca ↗
2026-11-05 · 🏢partnership · BioSpace · Evommune
- Evommune obtained rights outside Greater China to EVO570, Hinova's oral molecular glue degrader aimed at VAV1, an immune-cell signaling protein.
- Hinova receives $30M upfront ($20M cash plus $10M in pre-funded warrants), with milestones up to $1.1B and royalties on sales outside China.
- Rheumatoid arthritis is the lead indication; the deal follows Evommune's discontinuation of EVO756 in two skin diseases.
💡 PointsBased on public reportsThis reads as pipeline triage: after EVO756 failed in two skin diseases, Evommune buys a new story rather than waiting. The $30M upfront, a third of it in warrants, against $1.1B in milestones is a cheap option on an unproven target. VAV1 degradation is a bet that oral glues can out-position injectable biologics in rheumatoid arthritis. It also shows Chinese biotechs becoming default sources of ex-China assets.
Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap ↗
2026-11-05 · 🏢safety · BioSpace · Novartis
- Novartis says nine tumors have been reported in Zolgensma-treated patients since the 2019 approval; two show evidence of viral vector integration into DNA.
- The other seven have no established causal link to the therapy.
- Novartis notes tumor risk from integration is already in the label and that over 6,000 patients have received the therapy.
- SMA Europe says regulators are assessing the evidence.
💡 PointsBased on public reportsNine cases in 6,000-plus patients is a small number, but two with vector integration hit AAV's soft spot: durable, one-time dosing was always sold on the assumption that the vector stays episomal. Novartis can lean on the label, yet the real exposure is category-wide, since every AAV gene therapy rival and Novartis's own intrathecal follow-on will be asked the same question about long-term surveillance.
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma ↗
2026-11-05 · 🏢launch · BioSpace · Revolution Medicines
- Rasonque, approved in late August for previously treated metastatic pancreatic cancer, generated $198M in Q3 sales, far above analyst forecasts of $19M to $100M.
- More than 5,000 patients were reached, helped by early-access conversions; management says it is too early to judge the steady-state trajectory.
- Revolution reported a $407.5M quarterly net loss and $3.7B in cash, while Phase 3 first-line trials continue to advance.
💡 PointsBased on public reportsA $198M first quarter in a second-line pancreatic indication, part of it a one-time early-access conversion bump, says less about steady state than about unmet need: few drugs target RAS this directly. The real prize is first-line, where the Phase 3s and zoldonrasib sit. With $3.7B in cash, Revolution can fund that fight, and the bigger-pharma suitors will be watching.
RevMed's Rasonque shatters analyst estimates with $198M quarter ↗
2026-11-05 · 🏢financing · BioPharma Dive · T-Therapeutics
- UK-based T-Therapeutics closed a $133M Series B co-led by Advent Life Sciences and the British Business Bank.
- Eli Lilly, J&J's venture arm, Samsara BioCapital and Sofinnova also joined; a $32M Series A extension came last year.
- Its platform uses fully human T-cell receptors to build bispecific T-cell engagers against intracellular targets.
- Lead candidates TTX-008 (cancer) and TTX-018 (autoimmune) are preclinical; funds will go to proof-of-concept data.
💡 PointsBased on public reportsA $133M round for a preclinical company is a bet on the platform, not the assets. TCR-based engagers reach intracellular targets that antibody-based T-cell engagers can't, which is the real differentiator in a crowded bispecific field. Lilly and J&J's venture arm on the cap table read as option-building, and splitting oncology and autoimmune keeps the partnering menu wide.
T-Therapeutics reloads with a $133M megaround for bispecifics ↗
2026-11-04 · 🏢trial-result · Endpoints News · Spyre Therapeutics
- Spyre reported that SPY072, its anti-TL1A antibody, missed the primary endpoint in the psoriatic arthritis and axial spondyloarthritis parts of the Phase 2 SKYWAY basket trial.
- Safety was described as well tolerated and in line with the TL1A class.
- The company will stop developing the antibody in rheumatic diseases; an earlier rheumatoid arthritis cohort had also fallen below its internal bar.
- Focus shifts to hidradenitis suppurativa, in combination with an IL-17A/F inhibitor, with Week 16 data expected late 2027 or early 2028.
💡 PointsBased on public reportsThree rheumatic cohorts, three disappointments, and TL1A's autoimmune story now looks like a gut-and-skin play rather than a platform for every inflammatory disease. That leaves Spyre leaning on hidradenitis suppurativa, where pairing with an IL-17A/F blocker is the real bet. Data not before late 2027 means a long wait on a narrowing thesis.
Spyre's arthritis misses, Ideaya ends eye cancer trial ↗
